Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seropersistence after first booster and response to second booster with FSME-IMMUN in children, adolescents, and young adults
2009-009324-36Phase 4Completed
- Sponsor
- Pfizer
- Start
- Feb 2009
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of FSME-IMMUN in tick-borne encephalitis (TBE) (2 cohorts), sponsored by Pfizer. Primary endpoint: Immunogenicity. Started Feb 2009; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2009-009324-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009324-36.